Ranibizumab gains NICE approval for secondary macular oedema

Ranibizumab (Lucentis) can now be prescribed in the NHS for macular oedema secondary to central or branch retinal vein occlusion.

Ranibizumab is administered by specialists via intravitreal injection (pictured) | SCIENCE PHOTO LIBRARY
Ranibizumab is administered by specialists via intravitreal injection (pictured) | SCIENCE PHOTO LIBRARY

Ranibizumab can be used for macular oedema both as first-line therapy following central retinal vein occlusion and as a second-line treatment for branch retinal vein occlusion when laser photocoagulation has not been beneficial or cannot be used owing to the extent of macular haemorrhage. However, it must be provided by the manufacturer at a discount as agreed in the patient access scheme.

This recommendation follows recent positive decisions by NICE on the use of ranibizumab in wet age-related macular degeneration and diabetic macular oedema, after the implementation of a patient access sceme in 2012 reducing the cost of the drug to the NHS.

View Lucentis drug record

NICE guidance on ranibuzumab in macular oedema secondary to retinal vein occlusion 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more